Lisata Therapeutics Advances Certepetide and Forms Strategic Alliances in Q3

Lisata Therapeutics reported Q3 financial results, highlighting positive clinical progress for its lead therapy, certepetide, in solid tumors. The company entered a global license agreement with Catalent and a strategic alliance with GATC Health. Lisata exited Q3 with no debt and expects its cash balance to fund operations into early 2027. Operating expenses decreased 17.3% to $4.4 million, with a net loss of $4.2 million.